Literature DB >> 17051957

Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.

J C Walther, M Khorshid, A Gaya, P N Plowman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17051957     DOI： 10.1016/j.clon.2006.07.002

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  4 in total

1.  Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authors:  Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 2.  Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.

Authors:  Navneet Singh; Aditya Jindal; Digambar Behera
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

Authors:  Matthew K Wong; Alvis I Lo; Bing Lam; W K Lam; Mary S Ip; James C Ho
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-13       Impact factor: 3.333

4.  Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma.

Authors:  Koichi Kurishima; Katsunori Kagohashi; Takeo Mammoto; Hiroaki Satoh
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.